Status:
NOT_YET_RECRUITING
Anti-infection Therapy Based on mNGS Etiological Diagnosis and Infection After Liver Transplantation
Lead Sponsor:
Shenzhen Third People's Hospital
Conditions:
Infection
Eligibility:
All Genders
18-65 years
Brief Summary
Liver transplantation is the most efficacious treatment for end-stage liver disease; however, postoperative infection remains a major complication and leading cause of recipient mortality. Specificall...
Detailed Description
Liver transplantation has been established as a highly effective treatment for end-stage liver disease, with continuous advancements in surgical techniques and immunosuppressive regimens significantly...
Eligibility Criteria
Inclusion
- Recipient age \>18 years;
- Clinical diagnosis of infection in the donor with administered anti-infective treatment;
- Complete clinical data for both the donor and recipient.
Exclusion
- Recipient age \<18 years;
- Presence of surgery-related factors leading to death or infection, such as intraoperative cardiac arrest resulting in postoperative death, intraoperative bleeding exceeding 2000ml, postoperative complications like intestinal or bile leakage, graft dysfunction, or small liver syndrome;
- Incomplete clinical data for the donor or recipient
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06212115
Start Date
February 1 2024
End Date
December 30 2027
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Third People's Hospital
Shenzhen, Shenzhen, China